Voxelotor Shows Efficacy in Children Aged 2 to 4 Years With SCD
Researchers sought to determine whether voxelotor would be safe and effective in children aged 2 to less than 4 years with SCD.
Researchers sought to determine whether voxelotor would be safe and effective in children aged 2 to less than 4 years with SCD.
Researchers sought to determine whether the Psychosocial Assessment Tool would be able to identify families of patients with SCD in need of resource support.
Researchers sought to determine the use of prophylaxis for venous thromboembolism in adolescent patients with SCD.
Researchers sought to determine whether ferric carboxymaltose would improve anemia in pregnant women living in sub-Saharan Africa.
Researchers sought to determine whether patients with SCD were at higher risk of hospitalization or death due to COVID-19 infection.
The FDA has assigned a Prescription Drug User Fee Act goal date of August 28, 2023.
Researchers sought to identify any germline variants that have links to PNH.
Researchers sought to determine the impact of factor XII on the contact pathway in patients with SCD and how it affects complications.
Researchers sought to determine whether AIHA would prevent pregnant patients from safely carrying a baby to term.
Researchers sought to determine reasons for the association of SCD with rates of alloimmunization following transfusion therapy in both high-income and low-income countries.